C-Stem™ technology: Scaling-up iPS-derived cell therapy

C-Stem™ technology: Scaling-up iPS-derived cell therapy

TreeFrog Therapeutics has developed C-Stem, a technology allowing for the mass-production of iPS-derived cell therapies in large-scale bioreactors. C-stem is based on a proprietary high-throughput cell encapsulation technology which generates over 1,000 capsules per second. Each stem cell capsule constitutes a biomimetic micro-environment which recapitulates an in-vivo like stem cell niche. In the capsule, pluripotent stem cells self-organize to form an epiblast-like 3D stem cell microtissue which promotes exponential pluripotent stem cell growth, maintenance of homogenous pluripotency and high-fidelity chromosome segregation (preservation of genomic integrity). But the capsule is also protecting stem cells during manufacturing proceses. In fact, C-Stem allows for the scale-independent exponential amplification of hiPSCs and their differentiation into functional 3D microtissues in industrial bioreactors.

Pluripotent Stem Cell–Based Cancer Therapy: Promise and Challenges

Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy

Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression

Growth Factors for Induced Pluripotent Stem Cell Culturing - ACROBiosystems

Simple and efficient differentiation of human iPSCs into contractible skeletal muscles for muscular disease modeling

Frontiers Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Hold Lower Heterogeneity and Great Promise in Biological Research and Clinical Applications

Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy - ScienceDirect

Definitive Endodermal Cells Supply an in vitro Source of Mesenchymal Stem/Stromal Cells

Regenerative medicine: current research and perspective in pediatric surgery